Genexa v. KinderFarms: PGR Stay Halts Acetaminophen Patent Battle
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Genexa, Inc. v. KinderFarms, LLC |
| Case Number | 2:23-cv-08378 (C.D. Cal.) |
| Court | U.S. District Court for the Central District of California |
| Duration | Oct 2023 – Apr 2024 6 months |
| Outcome | Case Stayed Pending PTAB |
| Patents at Issue | |
| Accused Products | KinderFarms’ Infants’ Pain & Fever and Kids’ Pain & Fever |
Case Overview
The Parties
⚖️ Plaintiff
A consumer healthcare company positioning itself as America’s “clean medicine” brand, offering OTC medications formulated without artificial inactive ingredients.
🛡️ Defendant
Operates in the same competitive niche, marketing organic and clean-label pediatric OTC products, including its own Infants’ and Kids’ Pain & Fever acetaminophen lines.
The Patent at Issue
The asserted patent, U.S. Patent No. US11617795B2 (Application No. US17/817637), covers formulation technology in the pediatric acetaminophen space. Its commercial relevance relates to the use of specific inactive ingredients — including organic agave syrup as a sweetener and organic cherry flavor as a flavoring agent — in acetaminophen liquid formulations dosed at 160 mg per 5 mL.
Developing a new pharmaceutical formulation?
Check if your inactive ingredient combinations might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Central District of California **granted the parties’ joint stipulation to stay** all district court proceedings, including all pending deadlines, pending resolution of PTAB Post-Grant Review Proceeding **PGR2023-00051**. The court directed the Clerk to remove the case from the active docket. No damages were awarded, no injunction was issued, and no merits determination was reached at the district court level. The case was administratively closed on **April 16, 2024**.
The stay will remain in effect until: (1) settlement; (2) termination of the PGR; or (3) issuance of a Final Written Decision by the PTAB, anticipated by **March 25, 2025**. The parties are required to file joint status reports every 120 days.
Key Legal Issues
This case exemplifies the **”PTAB-first” defense strategy** that has become standard practice post-America Invents Act. Courts in the Central District of California have consistently granted stays pending PTAB proceedings when: (1) a petitioning party files early; (2) the case has not advanced to claim construction; and (3) a stay would simplify issues for trial. All three factors were present here.
The outcome also highlights that **PGR proceedings** — as distinct from IPR — may be the preferred challenge mechanism where claim scope extends to formulation combinations involving § 101 or § 103 arguments about natural/organic ingredients. Pharmaceutical formulation patents covering “clean” ingredient combinations may face heightened obviousness scrutiny at PTAB.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical formulation. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this technology space
- See which companies are most active in formulation patents
- Understand claim construction patterns for inactive ingredients
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Clean-label inactive ingredient combinations
1 Patent Under Review
At PTAB (PGR2023-00051)
Design-Around Options
Available for most formulation claims
✅ Key Takeaways
Joint stay stipulations pending PTAB can benefit both parties when PGR institution is likely — reducing litigation spend before the threshold validity question is resolved.
Search related case law →Central District of California remains receptive to early stays where PTAB proceedings are co-pending and discovery has not commenced.
Explore precedents →PGR (vs. IPR) is the appropriate challenge mechanism for post-AIA pharmaceutical formulation patents requiring broad invalidity grounds.
View PTAB analysis tools →Frequently Asked Questions
U.S. Patent No. US11617795B2 (Application No. US17/817637), covering formulation technology for organic infant acetaminophen liquid products.
Both parties jointly stipulated to a stay pending PTAB Post-Grant Review Proceeding PGR2023-00051, which will assess the patent’s validity. The Central District of California granted the stay for good cause, removing the case from active docket pending a PTAB Final Written Decision expected by March 25, 2025.
It confirms that formulation patents covering clean-label inactive ingredient combinations are being actively asserted and challenged in litigation, signaling IP practitioners to prioritize FTO analysis of inactive ingredient profiles in OTC pharmaceutical product development.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- USPTO Patent Center — US11617795B2
- PACER Case No. 2:23-cv-08378
- PTAB Docket PGR2023-00051
- U.S. Patent and Trademark Office — America Invents Act (AIA)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.